Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Active Primary Sjögren's Syndrome
NCT02915159Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2016
- Primary completion
- Aug 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in primary Sjögren's syndrome comparing Abatacept with Placebo (2 arms). Primary endpoint: EULAR Sjögren's Syndrome Disease Activity Index at Day 169. Started Dec 2016; status: completed.
02
Drugs
abatacept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT02915159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915159.